LASA Stock Overview
Engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Lasa Supergenerics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹29.12 |
| 52 Week High | ₹41.20 |
| 52 Week Low | ₹19.00 |
| Beta | 0.50 |
| 11 Month Change | 21.99% |
| 3 Month Change | 37.36% |
| 1 Year Change | -6.67% |
| 33 Year Change | -62.35% |
| 5 Year Change | 102.22% |
| Change since IPO | -80.22% |
Recent News & Updates
There's No Escaping Lasa Supergenerics Limited's (NSE:LASA) Muted Revenues
Aug 08
We Think Lasa Supergenerics (NSE:LASA) Has A Fair Chunk Of Debt
Jun 05Recent updates
There's No Escaping Lasa Supergenerics Limited's (NSE:LASA) Muted Revenues
Aug 08We Think Lasa Supergenerics (NSE:LASA) Has A Fair Chunk Of Debt
Jun 05Little Excitement Around Lasa Supergenerics Limited's (NSE:LASA) Revenues As Shares Take 26% Pounding
Mar 13Improved Revenues Required Before Lasa Supergenerics Limited (NSE:LASA) Stock's 25% Jump Looks Justified
Dec 28We Think Lasa Supergenerics (NSE:LASA) Has A Fair Chunk Of Debt
Jul 05Lasa Supergenerics (NSE:LASA) Is Carrying A Fair Bit Of Debt
Mar 28Lasa Supergenerics' (NSE:LASA) Dividend Will Be ₹0.25
Sep 02Would Lasa Supergenerics (NSE:LASA) Be Better Off With Less Debt?
Aug 13A Look At The Fair Value Of Lasa Supergenerics Limited (NSE:LASA)
Jun 21Is Lasa Supergenerics (NSE:LASA) Using Too Much Debt?
Dec 06Shareholder Returns
| LASA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.2% | 2.4% | 1.0% |
| 1Y | -6.7% | 60.9% | 44.7% |
Return vs Industry: LASA underperformed the Indian Pharmaceuticals industry which returned 60.9% over the past year.
Return vs Market: LASA underperformed the Indian Market which returned 44.7% over the past year.
Price Volatility
| LASA volatility | |
|---|---|
| LASA Average Weekly Movement | 8.6% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 9.8% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: LASA's share price has been volatile over the past 3 months.
Volatility Over Time: LASA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 89 | Omkar Herlekar | lasalabs.com |
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India. It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, riclabendazole, rafoxanide, ornidazole, ricobendazole, oxfendazole, closantel base, closantel sodium, nitroxynil, halquinol, and oxyclozanide, as well as 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use comprising potassium iodide.
Lasa Supergenerics Limited Fundamentals Summary
| LASA fundamental statistics | |
|---|---|
| Market cap | ₹1.46b |
| Earnings (TTM) | -₹195.13m |
| Revenue (TTM) | ₹1.05b |
1.4x
P/S Ratio-7.5x
P/E RatioIs LASA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LASA income statement (TTM) | |
|---|---|
| Revenue | ₹1.05b |
| Cost of Revenue | ₹769.81m |
| Gross Profit | ₹276.33m |
| Other Expenses | ₹471.46m |
| Earnings | -₹195.13m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.89 |
| Gross Margin | 26.41% |
| Net Profit Margin | -18.65% |
| Debt/Equity Ratio | 22.8% |
How did LASA perform over the long term?
See historical performance and comparison